$HCA

HCA earnings beat by $0.57, revenue topped estimates

HCA Healthcare (HCA) reported Q3 EPS of $7.22, beating estimates by $0.57, with revenue at $19.85B, exceeding expectations. The stock is up 17.55% over 3 months but down 0.26% year-over-year. InvestingPro rates its financial health as 'great performance'.

Original reporting
Published Oct 27, 2026, 11:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HCA
Bullish
high confidence
Mentioned
$HCA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HCABullishHigh
01

Why it matters

The earnings beat may trigger a short‑term rally, but investors will watch forward guidance for sustainability.

02

Market read

Strong earnings beat for a large‑cap health‑care stock, likely to generate buying interest.

03

What to watch

Guidance outlook and payer mix were not disclosed; future performance may be muted.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

HCA is a leading provider of acute care services in the United States.

Company-level read

Ticker impact

$HCABullishHigh confidence
Context

HCA reported Q3 EPS of $7.22, beating estimates by $0.57 and revenue of $19.85B versus $19.33B consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat on both earnings and revenue for a large‑cap health‑care operator typically triggers buying interest, especially after hours.

Market effects

May lift other hospital operators and health‑care services stocks.

Positive for U.S. health‑care sector in the near term.

Limited to U.S. markets but could influence global health‑care indices.

Counterpoint

If the beat is already priced in, the stock could face short‑term profit taking.

Key entities

  • HCA Healthcare

    U.S. hospital operator that reported Q3 earnings.

Related articles

$HCAMed

BofA raises HCA Healthcare stock price target on solid execution

BofA Securities raised its price target on HCA Healthcare (NYSE:HCA) to $500 from $450, citing solid execution and upside from supplemental Medicaid programs. The company's Q3 EBITDA exceeded estimates, with revenue of $19.85B and EPS of $7.22. HCA maintained its guidance range but faces near-term headwinds. The stock trades at an EV/EBITDA of 9.6x and a P/E ratio of 14.85.

$HCAMed

HCA Healthcare Inc (HCA) Q3 2026 Earnings Call Highlights: 22 Straight Quarters

HCA Healthcare (HCA) reported Q3 2026 earnings, highlighting a 19% decline in exchange equivalent admissions, a $400M unfavorable EBITDA impact, and reduced elective surgical volumes. The company expects $550M-$650M less in Medicaid supplemental payments in 2027. HCA anticipates 2027 earnings to be generally consistent with 2026, citing exchange headwinds and reduced supplemental payments.

$HCAMedAI 8/10

What HCA Healthcare (HCA) Said on Its Q3 Earnings Call

HCA Healthcare reported $50M in incremental Medicaid benefits in Q3, raising its 2026 estimate to $600M-$800M. Costs were flat, but professional fees rose 12%. HCA reaffirmed 2026 guidance, expecting upper-half results. For 2027, it anticipates strong demand and earnings similar to 2026. The company spent $1.36B on capital expenditures, repurchased $3B in shares, and paid $165M in dividends.

$HCAHighAI 9/10

HCA (HCA) Q3 2026 Earnings Call Transcript

HCA Healthcare reported Q3 2026 revenue of $19.849 billion, up 3.6% YoY, with net income of $1.579 billion. EPS grew 4.4% to $7.27. Adjusted EBITDA rose 1.2% to $3.918 billion. Volume growth continued, but payer mix shifts impacted earnings. The company raised full-year revenue and EBITDA guidance. Management expects stable 2027 earnings despite Medicaid payment headwinds.

$HCAHighAI 8/10

HCA signals flat 2027 earnings as Medicaid payments drop; shares slide

HCA Healthcare forecasted flat 2027 earnings, citing lower Medicaid payments and rising uninsured patients, causing shares to drop over 5%. CEO Sam Hazen attributed the outlook to a fluid policy environment. Analysts expect 2027 EPS of $32.14, below the company's implied guidance. HCA's Q3 adjusted profit was $7.22 per share on revenue of $19.85 billion, beating estimates. The company expects 2026 EPS between $28.70 and $30.50 on revenue of $77.0B-$79.5B.

$HCAMedAI 8/10

HCA Healthcare, Inc. Q3 2026 Earnings Call Summary

HCA Healthcare reported Q3 2026 volume growth of 3%, driven by demand across various service lines. The company offset payer mix pressure through higher revenue per admission and improved contract collections. Elective surgical volumes faced challenges due to federal policy changes. HCA maintained flat same-facility costs despite inflation. The company anticipates 2027 earnings to be generally consistent with 2026, with 2% to 3% volume growth.